Browse drugs

… lack of efficacy, six patient decision, five pregnancy) and 37 ixekizumab patients (seven toxicity, 17 loss of response, one patient deci…

… months (erenumab), 12.9 months (fremanezumab) and 19.0 months (galcanezumab). Mean MDM reduction was: galcanezumab –7.3 days/month (p<0.000…

… combination of trifluridine/tipiracil (FTD-TPI) in addition to bevacizumab (BEV) has demonstrated to have the potential to extend progress…

…ndependent t-tests.Results ChatGPT-5 substantially outperformed ChatGPT-4o. The mean accuracy of correctly summarising ADRs was 77.9% (SD …

…g reports of suicidal ideation and behaviors in patients taking GLP-1 RAs. This study assessed a potential association with intentional s…

…2% female; 96.0% Caucasian). At enrolment, 88.2% were receiving hydroxychloroquine (n=179). Overweight/obesity prevalence was 60.1%, and 83.3% had…

…978520) was to evaluate the achievement of LLDAS and DORIS with upadacitinib (UPA) monotherapy (30 mg) vs placebo (PBO).Methods LLDAS and DO…

… of nephropathy for each possible AER in patients on placebo or irbesartan 150mg daily or irbesartan 300mg daily provide a personalised pr…

…s aged 18+ years from 38 states with data on state recreational cannabis legalisation and retail sales availability. Using multinomial l…

…een 1L and second-line (2L) therapies) was twice as long versus sunitinib. TFS and survival states for ICI plus vascular endothelial grow…

…TI, between multiple ICS doses and oral candidiasis and between budesonide dose and cataract.Conclusions ICSs are correlated with the esca…

…vacaine produced few significant differences when compared with bupivacaine alone.Discussion Using ex vivo electrophysiology, we identified…